Why This Matters for Your Career
Viatris is hiring 2 roles related to this product
MESALAMINE (mesalamine) by Viatris. Approved for aminosalicylate [epc]. First approved in 2019.
Drug data last refreshed 3h ago
Aminosalicylate
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
Worked on MESALAMINE at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Viatris is hiring 2 roles related to this product